(Boston, MA) Principal Associate Scientist sought by Ascidian Therapeutics, Inc. to
design, validate, execute, and interpret experiments to improve therapeutic performance
of designer RNA editing molecules & contribute to characterization of drug candidates to
support Ascidian’s Roche Collaboration. Req.’s Master’s Deg. in Molecular/Cellular
Bio., Bio. Chem. or rel. field & 3 yrs rel. exp. or Bach’s Deg. & 5 yrs rel. exp. Must have
experience in RNA therapeutics with a focus on pre-mRNA splicing and protein
translation; designing and cloning RNA exon-editing molecules and designing assays to
measure RNA editing; optimization and preparation of custom Illumina libraries;
bioinformatic analysis of the libraries; cell culture, ddPCR, qPCR and protein extraction
and characterization by JESS and western blot, Sanger sequence analysis; use of
sequence design and analysis software.
No calls.
Salary: $ 112,017 to $118,400 per year.
The final salary offer will be determined based on several factors, including the candidate’s relevant experience, specific skills, and internal equity.
Ascidian Therapeutics is redefining the treatment of disease by rewriting RNA. By editing exons at the RNA level, Ascidian therapies enable precise post-transcriptional editing of genes, resulting in full-length, functional proteins at the right levels, in the right cells, at the right time. With active discovery and preclinical programs in ophthalmology, neurological and neuromuscular disorders, and other rare diseases, Ascidian is opening new therapeutic possibilities for patients in need of breakthroughs. For more information, visit www.ascidian-tx.com.
